"Our work may open a new field of experimental therapeutics as combating the eventual development of liver metastases by targeting immune suppressive cells in the livers, in patients with early cancer can have great benefit,” said Dr. George Miller, a scientist involved in the work from the departments of surgery and cell biology at the New York University School of Medicine (New York, NY, USA).
Dr. Miller and colleagues reached this conclusion after conducting experiments in lab mice. In the experiments, the investigators used mice that spontaneously developed pancreatic cancer because of a mutation (Kras-mutation) in the progenitor cells of the pancreas, as well as mice with advanced colon cancers that spread to the abdomen. They then studied the expansion of immune suppressive cells in the liver from a very early stage in the cancer development to determine the immune phenotype, stimulus for recruitment, inhibitory effects, and tumor-enabling function of these cells. The study's results suggest that fighting immune suppressive cells in the liver early after cancer development may prevent the metastasis of cancer to this vital organ.
The study's findings were published in the April 2010 issue of Journal of Leukocyte Biology (JLB). "This study could represent one of those ‘a-ha' moments in science where one idea or experiment opens up entirely new ways of approaching and understanding a problem,” said Luis Montaner, editor-in-chief of JLB. "Physicians have known that the spread of cancer to the liver is far too common to occur by chance. Now we know that the immune system likely plays a role in facilitating this process. The next step, obviously, is to learn more so we can prevent it from happening.”
Related Links:
New York University School of Medicine
